Skip to Main Content
Contribute Try STAT+ Today

Although 18 innovative antibiotics were approved by regulators in the wealthiest nations over the past decade, a new analysis finds few of these life-saving medicines were accessible due to delayed product launches stemming from concerns over sales and profitability.

Of those new antibiotics, most were available only in the U.S., the U.K., and Sweden, while only two were accessible in all 14 high-income countries that were examined. Just four antibiotics were launched in all of the 11 European countries where approvals and product launches were reviewed, according to the analysis published in Clinical Infectious Diseases.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment